Revenues (Tables)

12 Months Ended

Dec. 31, 2020

Revenue from Contract with Customer [Abstract]

Revenues by product are summarized as follows:


	For the Years Ended December 31,
	2020						2019						2018
(In millions)	United States		Rest of World		Total		United States		Rest of World		Total		United States		Rest of World		Total
Multiple Sclerosis (MS):
Fumarate*	$	2,742.0	$	1,163.4	$	3,905.4	$	3,312.0	$	1,126.2	$	4,438.2	$	3,253.2	$	1,020.9	$	4,274.1
Interferon**	1,273.5		604.0		1,877.5		1,426.6		675.2		2,101.8		1,668.3		694.7		2,363.0
TYSABRI	1,096.8		849.3		1,946.1		1,041.8		850.4		1,892.2		1,025.0		839.0		1,864.0
FAMPYRA	—		103.1		103.1		—		97.1		97.1		—		92.7		92.7
ZINBRYTA	—		—		—		—		—		—		—		1.4		1.4
Subtotal: MS	5,112.3		2,719.8		7,832.1		5,780.4		2,748.9		8,529.3		5,946.5		2,648.7		8,595.2

Spinal Muscular Atrophy:
SPINRAZA	787.8		1,264.3		2,052.1		933.4		1,163.6		2,097.0		854.0		870.2		1,724.2

Biosimilars:
BENEPALI	—		481.6		481.6		—		486.2		486.2		—		485.2		485.2
IMRALDI	—		216.3		216.3		—		184.0		184.0		—		16.7		16.7
FLIXABI	—		97.9		97.9		—		68.1		68.1		—		43.2		43.2
Subtotal: Biosimilars	—		795.8		795.8		—		738.3		738.3		—		545.1		545.1

Other:
FUMADERM	—		12.2		12.2		—		15.2		15.2		—		22.3		22.3

Total product revenues	$	5,900.1	$	4,792.1	$	10,692.2	$	6,713.8	$	4,666.0	$	11,379.8	$	6,800.5	$	4,086.3	$	10,886.8

*Fumarate includes TECFIDERA and VUMERITY. VUMERITY became commercially available in the U.S. in November 2019.

**Interferon includes AVONEX and PLEGRIDY.

Analysis of change in reserves

An analysis of the change in reserves for discounts and allowances is summarized as follows:


	December 31, 2020
(In millions)	Discounts		Contractual Adjustments		Returns		Total
Beginning balance	$	131.1	$	1,027.3	$	40.5	$	1,198.9
Current provisions relating to sales in current year	774.7		3,308.8		19.0		4,102.5
Adjustments relating to prior years	(1.0)		(54.0)		1.3		(53.7)
Payments/returns relating to sales in current year	(635.1)		(2,426.1)		—		(3,061.2)
Payments/returns relating to sales in prior years	(128.3)		(763.0)		(19.2)		(910.5)
Ending balance	$	141.4	$	1,093.0	$	41.6	$	1,276.0


	December 31, 2019
(In millions)	Discounts		Contractual Adjustments		Returns		Total
Beginning balance	$	127.8	$	888.8	$	34.7	$	1,051.3
Current provisions relating to sales in current year	666.2		3,011.5		20.9		3,698.6
Adjustments relating to prior years	0.3		(54.1)		5.5		(48.3)
Payments/returns relating to sales in current year	(535.5)		(2,242.9)		(0.2)		(2,778.6)
Payments/returns relating to sales in prior years	(127.7)		(576.0)		(20.4)		(724.1)
Ending balance	$	131.1	$	1,027.3	$	40.5	$	1,198.9


	December 31, 2018
(In millions)	Discounts		Contractual Adjustments		Returns		Total
Beginning balance	$	109.6	$	606.0	$	46.0	$	761.6
Current provisions relating to sales in current year	679.3		2,686.7		23.1		3,389.1
Adjustments relating to prior years	(0.3)		(10.0)		(1.8)		(12.1)
Payments/returns relating to sales in current year	(551.7)		(1,887.6)		(1.1)		(2,440.4)
Payments/returns relating to sales in prior years	(109.1)		(506.3)		(31.5)		(646.9)
Ending balance	$	127.8	$	888.8	$	34.7	$	1,051.3

Total reserves included in consolidated balance sheet

The total reserves above, which are included in our consolidated balance sheets, are summarized as follows:


	As of December 31,
(In millions)	2020		2019
Reduction of accounts receivable	$	195.4	$	197.8
Component of accrued expenses and other	1,080.6		1,001.1
Total revenue-related reserves	$	1,276.0	$	1,198.9

Revenues from anti-CD20 therapeutic programs

Revenues from anti-CD20 therapeutic programs are summarized in the table below. For purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.


	For the Years Ended December 31,
(In millions)	2020		2019		2018
Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA	$	1,080.2	$	1,542.4	$	1,431.9
Other revenues from anti-CD20 therapeutic programs	897.6		748.0		548.3
Total revenues from anti-CD20 therapeutic programs	$	1,977.8	$	2,290.4	$	1,980.2

Revenues from anti-CD20 therapeutic programs are summarized as follows:


	For the Years Ended December 31,
(In millions)	2020		2019		2018
Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses	$	1,080.2	$	1,542.4	$	1,431.9
Other revenues from anti-CD20 therapeutic programs	897.6		748.0		548.3
Total revenues from anti-CD20 therapeutic programs	$	1,977.8	$	2,290.4	$	1,980.2

Other revenues

Other revenues are summarized as follows:


	For the Years Ended December 31,
(In millions)	2020		2019		2018
Revenues from collaborative and other relationships:
Revenues earned under our technical development agreement, manufacturing service agreements and royalty revenues on biosimilar products with Samsung Bioepis	$	20.9	$	106.2	$	96.4
Other revenues from collaborative and other relationships	0.7		—		(8.6)
Other royalty and corporate revenues:
Royalty	33.9		17.0		38.7
Other corporate	719.1		584.5		459.4
Total other revenues	$	774.6	$	707.7	$	585.9